CD44 variant isoforms (CD44v) have been shown to be important factors in adverse prognosis in hematological malignancies. To investigate whether CD44 expression is associated with malignant transformation in multiple myeloma, RNA and protein expression of CD44 standard (CD44s) and CD44v4, v6, v9, v10 containing isoforms was compared on bone marrow plasma cells from normal individuals and myeloma patients at different stages of disease. CD44s protein expression is strongly decreased on myeloma plasma cells and non-malignant B cells in affected bone marrow of myeloma patients, while no differences in CD44s expression were found between blood B cells from normal individuals and myeloma patients. CD44v isoforms were expressed on plasma cells in the majority of normal and myeloma samples analyzed. CD44v9 and v10 containing isoforms were differentially expressed on bone marrow plasma cells from normal individuals (predominantly CD44v9 
Introduction
Adhesion molecules direct migration of antigen-selected plasmacytoid cells from the lymphoid organs to the bone marrow and their subsequent differentiation into plasma cells. 1, 2 In multiple myeloma, a disorder in which neoplastic plasma cells accumulate in the bone marrow, changes in the expression of adhesion molecules have been related to tumor growth and survival. [3] [4] [5] [6] Binding of myeloma plasma cells to different cell types in the bone marrow environment triggers the production of the myeloma growth factor, IL-6. [7] [8] [9] Additionally, the susceptibility of the tumor cells for IL-6 increases, resulting in the induction of myeloma growth in vitro. 10 One of the adhesion molecules involved in the interplay of myeloma plasma cells with their environment is CD44. 8, 9 The transmembrane glycoprotein CD44 is encoded by a single gene and reaches an enormous complexity by alternative splicing of the nuclear RNA and by post-translational modifications. 11 Apart from the standard form of CD44 (CD44s), the alternative splicing of 10 additional exons produces multiple exon combinations encoding the different variant isoforms. Stimulation of lymphocytes results in the upregulation of CD44 variant isoforms (CD44v), while resting lymphocytes do not express detectable levels of CD44v. [12] [13] [14] CD44v might contribute to the many functions of the CD44 Correspondence: AC Bloem, Dept of Immunology, University Hospital Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; Fax: 030 2517107 Received 15 June 1998; accepted 21 July 1998 molecule, such as early hematopoiesis, 15 rolling on endothelial cells at sites of inflammation, 16 apoptosis and shedding. 17 In a spontaneous rat metastasis model expression of CD44v isoforms has been decisive for the metastatic capacity of cells. 18 Changes in the expression of CD44 variant isoforms have also been shown in several human tumor tissues. In colon, renal and gastric carcinomas, an upregulation of CD44 isoforms is generally accompanying disease progression, while in mammary tumors, neuroblastoma and squamous cell carcinoma an inverse correlation between CD44 isoforms and disease progression has been found. 19 In hematological disorders, such as non-Hodgkin's lymphoma and acute myeloblastic leukemia, expression of CD44v6 isoforms is associated with unfavorable prognosis. 20, 21 We have previously shown that CD44v9 isoforms are associated with advanced disease and a short overall survival in multiple myeloma, and hence represent a new prognostic factor. 22 In multiple myeloma, the median time of survival from the time of diagnosis is 3 to 4 years. Most patients initially respond to chemotherapy, but nearly all relapse and become refractory for conventional treatment. 23, 24 Since CD44v expression depends on cell type, stage of development, activation, or alternatively is associated with malignant transformation and/or tumor progression, we compared expression of CD44 isoforms in bone marrow plasma cells of healthy individuals and malignant plasma cells of myeloma patients in a stable and progressive stage of the disease. The results show that CD44 isoforms can be used to distinguish between plasma cells from normal and myeloma bone marrow and that plasma cells from myeloma patients with stable or progressive disease show expression of different CD44 isoform combinations.
Materials and methods

Myeloma patients and healthy donors
Normal bone marrow aspirates were obtained after informed consent from 18 healthy individuals that were donors for an allogeneic bone marrow transplant or underwent coronary bypass surgery. Myeloma bone marrow was obtained from patients that were in stage III according to the criteria of Salmon and Durie. 25 Myeloma patients were divided in two groups: patients with stable disease and progressive disease. Patients with stable disease (n = 13; nine patients treated and four untreated at time of sampling) had no or mild clinical symptoms and their M protein remained stable for at least 3 months before the time of analysis. The plasma cell labeling index in these patients samples was Ͻ0.6%. Patients with progressive disease (n = 19; eight treated and 11 untreated at time of sampling) had symptomatic disease and an increase in M protein for at least 25% in the 3 months preceding the analysis and a plasma cell labeling index Ͼ0.6%. In both groups, no significant differences were observed in CD44 expression profiles between the treated and untreated patients.
Blood was collected by vena puncture from 12 healthy volunteers and from seven myeloma patients with stable disease and nine with progressive disease.
Flow cytometric analysis
Mononuclear cells from bone marrow and blood were obtained by using Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) density centrifugation. Cells were either used directly for immunofluorescence staining or stored in liquid nitrogen. The result of a flow cytometric measurement is expressed as fluorescence ratio (FR). This is the ratio between the mean fluorescence intensity of primary antibody and isotype control stained cells. The mean expression of an individual CD44 isoform within a group of individuals is presented as mean FR (mFR) ± standard error of the mean (s.e.m.). A FR of two times background was considered positive.
Purification of plasma cells from normal and myeloma mononuclear bone marrow cells was performed using a FACStar Plus (Becton Dickinson). Plasma cells were defined by CD38 expression (CD38 +++ ) and forward and orthogonal light scatter properties (see above). Sorted cells were evaluated by May-Grü nwald-Giemsa staining.
Reverse transcription PCR
Sorted plasma cells were stored in GT buffer (guanidinium isothiocyanate 4 M, Tris-HCl 50 mM, pH 7.6, EDTA 10 mM, Nlauryl sarcosine 2%, sodium acetate pH 5.2, ␤-mercaptoethanol 1%) at −80°C. Total cellular RNA was prepared using 10 4 to 10 5 sorted plasma cells from normal and myeloma bone marrow. A CD44-specific PCR and subsequent hybridization with exon-specific probes was performed as described previously. 20 
Statistical analysis
For statistical analysis, a two-sided Student's t-test was used to compare mean FRs. In case of unequal variances, Welch's approximate t was used. A two-sided Fisher's exact test was used to compare CD44v co-expression profiles. May-Grü nwald-Giemsa staining of CD38 +++ purified plasma cells in normal (a) and myeloma (b) bone marrow (magnification ×250).
Results
Identification of plasma cells and B cells in normal and myeloma bone marrow
of monoclonal plasma cells in the myeloma bone marrow samples ranged from 3 to 95%. Sorting of the myeloma plasma cells resulted in cell populations consisting of more than 99% plasma cells (Figure 1b) . Both normal and myeloma bone marrow B lineage cells consisted of 50-95% surface Ig + cells, expressing normal kappa/lambda ratios (data not shown).
Decreased expression of CD44s in myeloma bone marrow
Plasma cells in bone marrow of normal individuals and myeloma patients in a stable and progressive phase of their disease were analyzed for CD44s protein expression by flow cytometric analysis (Figure 2a ). CD44s expression on normal plasma cells (16.8 ± 2.5) was significantly higher compared to myeloma plasma cells from patients with stable (6.8 ± 2.8, P Ͻ 0.02) and progressive disease (9.9 ± 1.9, P Ͻ 0.04). Similar results were obtained when B cells in bone marrow were analyzed (Figure 2b ). CD44s expression on B cells in normal bone marrow (32.9 ± 4.3) was significantly higher than on normal B cells in affected bone marrow of myeloma patients, irrespective of stage of disease (stable disease: 17.0 ± 3.6, P Ͻ 0.03; progressive disease: 9.4 ± 2.3, P Ͻ 0.0001). CD44s expression on bone marrow-derived B cells from normal individuals and myeloma patients with stable disease was higher than on the plasma cells; B cells from patients with progressive disease showed the same decreased CD44s expression seen on the plasma cells. Analysis of CD44s expression on B cells in blood (Figure 2c ), did not reveal significant differences between normal individuals (20.5 ± 2.6) and myeloma patients (stable disease: 27.2 ± 9.6; and progressive disease: 18.3 ± 3.9).
Association of CD44 variant expression with malignancy and stage of disease in multiple myeloma
Data from the flow cytometric analysis of CD44v4, v6, v9 and v10 protein expression on normal and myeloma bone marrow plasma cells are listed in Table 1 . Representative FACS staining profiles are shown in Figure 3 . Plasma cells showed uniform staining within individual samples and heterogeneity in staining intensity when different samples were compared. In 78% (14/18) of the normal individuals tested, plasma cells expressed one or more CD44 variant(s). This percentage was 69% (9/13) and 68% (13/19) for myeloma patients with stable and progressive disease, respectively.
Depending on the stage of disease, either CD44v9 or CD44v10 expression significantly differed between myeloma and normal plasma cells. Compared to normal plasma cells, myeloma plasma cells from patients with stable disease expressed significant lower levels of CD44v9 (P Ͻ 0.002), while in patients with progressive disease a significant lower expression of CD44v10 was found (P Ͻ 0.03). Moreover, on myeloma plasma cells, CD44v9 expression significantly differed between patients with stable and progressive disease (P Ͻ 0.02). No significant difference in CD44v4 or CD44v6 expression was found between normal and myeloma plasma cells.
Analysis of CD44v co-expression profiles on plasma cells in individual samples revealed that CD44v9 and CD44v10 expression (irrespective of CD44v4 or CD44v6 expression) discriminated between normal and myeloma plasma cells, and also between myeloma plasma cells from patients with stable and progressive disease. The combination of CD44v9 and CD44v10 (CD44v9 + v10 + ) was preferentially found on normal plasma cells (Figure 4a ), 64% of CD44v + normal bone marrow samples were positive for both CD44v9 and (Figure 4b ), while this combination was detected in only 7% of the CD44v + samples from normal bone marrow and 15% of the CD44v + bone marrow samples from patients with progressive disease. Expression of CD44v9 in the (Figure 4c ). This expression pattern was found on plasma cells in 69% of the CD44v + bone marrow samples of myeloma patients with progressive disease, whereas only 22% of the CD44v + normal bone marrow samples and 11% of the CD44v + myeloma bone marrow samples from patients with stable disease showed this phenotype. Co-expression of CD44v9 and CD44v10 (CD44v9 
Exon composition of CD44 mRNA transcripts in normal and myeloma bone marrow plasma cells
CD44 isoform composition at the RNA level was evaluated by semiquantitative RT-PCR, followed by Southern blotting and detection with CD44 exon-specific probes ( Figure 5 ). This analysis was performed on purified plasma cells derived from bone marrow from normal individuals (n = 4, lanes 1-4) and myeloma patients with stable (n = 2, lanes 15-16) and progressive disease (n = 11, lanes 5-14, 17). The corresponding CD44v9 and v10 protein expression profiles on these plasma cells are listed in Table 2 . Normal plasma cell samples all Based on the protein expression of individual CD44v isoforms a compilation was made of co-expression profiles of CD44v In all plasma cell samples multiple CD44 transcripts were found. The differences observed in CD44v protein expression were not accompanied by differences at the RNA transcript level; plasma cells expressing different CD44v isoforms contained transcripts that were comparable in number and composition. Exceptions were CD44v9 + v10 − plasma cells from patients with progressive disease where additionally large transcripts (three out of five patients, lanes 8, 9 and 14) or transcripts containing single exon v9 (two out of five patients, lanes 8 and 14) were found. These transcripts were not present in all other plasma cell samples analyzed.
Discussion
This study shows that CD44 standard and CD44 variant isoforms are differentially expressed on bone marrow derived normal and myeloma plasma cells. Expression of CD44s is significantly lower on myeloma plasma cells compared to normal plasma cells. Furthermore, co-expression of CD44v9 and v10 distinguishes between normal and myeloma plasma cells and, in addition, between tumor cells from patients with stable and progressive disease.
The decreased CD44s expression on myeloma plasma cells does not seem to be an inherent property of the tumor cells, since normal B cells in the affected bone marrow also have significantly lower levels of CD44s as compared to B cells in normal bone marrow. B cells in the blood from myeloma patients do not differ in CD44s expression from B cells in blood from healthy individuals. This emphasizes that the changes in CD44s expression in myeloma are not systemic, but confined to the bone marrow environment. Our observation is in contrast to previously published data, 5 in which no significant differences were observed in CD44s expression between normal and myeloma plasma cells. For other tumors, such as neuroblastomas and squamous cell carcinomas, 19 a downregulation of CD44s has been reported.
Here we show for the first time that the CD44 variant profile can be used as a prognostic parameter in disease progression in multiple myeloma, and for differentiation between normal and myeloma plasma cells. Differential expression of CD44v9 and v10 containing isoforms significantly distinguishes between normal (CD44v9 − ) disease. No significant differences in CD44v4 and v6 expression between normal and myeloma plasma cells were found. These data confirm and extend our previous finding that CD44v9 expression detected by immunohistochemical staining of myeloma bone marrow biopsies on another cohort of myeloma patients, associates with advanced stage, progressive disease and shorter overall survival of myeloma patients. 22 The association with stable disease and CD44v10 expression has also been described for non-Hodgkin lymphomas, 26 where CD44v10 was higher expressed on blood mononuclear cells from patients in remission, compared to patients with progressive disease.
Several mechanisms may contribute to the observed differential expression of CD44s and CD44v on normal and myeloma plasma cells. A changed local cytokine environment may result in these changes, because cytokines produced by cellular components from myeloma bone marrow differ from their normal counterparts 27 and CD44s and CD44v expression 
Table 2
Flow cytometric analysis of CD44v9 and CD44v10 expression on individual plasma cell samples from normal and myeloma bone marrow. The values cited represent fluorescence ratios (for definition see Materials and methods) of CD44v9 and CD44v10 on individual plasma cell samples corresponding to the samples in Figure 5 (number 1 to 17 corresponds to lane 1 to 17 in Figure 5 ), from normal individuals (N) and myeloma patients with stable (MM (s)) and progressive (MM (p)) disease. Fluorescence ratios Ͼ2 are considered positive and those values are given in bold.
can be controlled by cytokines. 14 A second explanation for the differential expression of CD44s and CD44v at the protein level might relate to shedding of CD44 moieties from the cell surface. It has been suggested that shedding is an important regulatory mechanism to control cell surface expression of CD44s and CD44v in cell lines 28 and leukocytes. 29 Recently, it has been shown that presence of glycosaminoglycan side chains on the CD44v3 exon product prevents shedding of these CD44 isoform moieties. 30 This suggests that CD44v expression might even be (indirectly) regulated via glycosylation of CD44v exon products. A third explanation might be aberrant control of the splicing machinery, resulting in the generation of different CD44 RNA species and hence protein molecules. However, analysis of CD44 transcripts in purified normal and myeloma plasma cells does not support this last option. The different CD44v profiles at the protein level could not be correlated with differential expression of characteristic CD44 RNA transcripts in the majority of the myeloma samples analyzed. Exception were CD44v9 + v10 − plasma cells from patients with progressive disease, where extra (large) transcripts were detected that were not found in normal or in nonCD44v9
− myeloma plasma cells. Such large and complex CD44 transcripts containing multiple variant exons are also found in aggressive non-Hodgkin lymphomas 20 and are transiently expressed during activation of normal lymphocytes. 20 This suggests that presence of these transcripts may reflect a state of activation of CD44v9 + v10 − tumor cells. This agrees with the absence of such large transcripts in plasma cells from normal individuals and myeloma patients with stable disease. Recently it was described that signal transduction can be coupled to alternative pre-mRNA splicing by a composite splice regulator. 31 This could be another mechanism that changes the CD44 splicing patterns during physiological (development and lymphocyte activation) and pathological (tumor progression) conditions. Whether one or more of the above described mechanisms are involved in the differential expression of CD44 variant isoforms on normal and myeloma plasma cells is currently under study.
Adhesion molecules are vital for the generation of normal plasma cells; they allow entrance of plasma blastoid cells in the bone marrow compartment and facilitate terminal B cell differentiation via interaction with bone marrow stromal cells and the extracellular matrix. 1, 2, 32, 33 Absence of one or more adhesion molecule(s) from myeloma plasma cells, including CD44s, correlates with reduced binding to bone marrow stromal cells (A Bloem, unpublished observations). This suggests that decreased CD44s expression may contribute to enhanced mobility of myeloma cells and dissemination that is seen in the majority of patients with multiple myeloma. 34, 35 It is unclear which role CD44 variant isoforms play during normal B cell differentiation and how CD44v9 relates to the pathogenesis of myeloma. It has been suggested that CD44v isoforms are not involved in homing to bone marrow but regulate cell growth possibly via triggering secretion of growth factors. 30 In multiple myeloma the most important growth factor is IL-6. 24 Since binding of myeloma plasma cells to bone marrow stromal cells induces IL-6 secretion, 7, 8 CD44v9 may be involved in this process. Alternatively, CD44v9 may bind to bone marrow stromal cells or ECM components and associate with transmembrane proteins with signaling properties, thereby indirectly linking CD44v9 to signaling cascades involved in cell activation or growth regulation.
This study shows that CD44s and CD44v expression distinguishes between bone marrow derived normal, and myeloma plasma cells from patients with stable and progressive disease, both at the protein and the RNA level. The use of the CD44v profile as a prognostic parameter predicting disease progression or eminent relapse is under study in a large cohort of myeloma patients. Furthermore, studies are in progress to answer the question whether the relation between CD44v9 expression and activity of disease in myeloma reflects the role of CD44v9 during normal B cell differentiation. Elucidation of its role in the pathogenesis of myeloma may prove critical in understanding how normal plasma cells are generated and may provide the rationale for new CD44v9 directed therapeutic strategies.
